Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imbruvica

- PMLiVE

AbbVie’s PARP inhibitor veliparib fails to deliver

Phase III trials show no increase in clinical benefit

- PMLiVE

AbbVie and J&J file first non-cancer use for Imbruvica with FDA

Seeks FDA approval to treat GVHD patients

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

- PMLiVE

AbbVie weak on new drug sales, but Humira stays strong

World’s biggest-selling drug has record quarter while Imbruvica and Venclexta fall short

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

- PMLiVE

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

Institute reverses its initial verdict on Janssen's oncology treatment

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

- PMLiVE

Two new hepatitis C therapies fast-tracked in Europe

EMA speeds review process for Gilead and AbbVie treatments

- PMLiVE

Ashley Communications celebrates 20 years of medical communications

Looks forward with new business wins, including AbbVie and Merck & Co accounts

EU flag

EU clears AbbVie’s leukaemia drug venetoclax

Becomes the first BCL-2 inhibitor to be approved by the EMA

- PMLiVE

AbbVie’s ‘The Story of HS’ wins at PMEA 2016

Takes top prize in Excellence in Training Capability Development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links